Association Between ACE2 and Lung Diseases

Cheng Su; Cai Li; Xinyi Hu; Jing Wang; Linlin Liu; Xianfeng Zhang; Yeqing Tong

doi:10.2147/IDR.S445180

Association Between ACE2 and Lung Diseases

Infect Drug Resist. 2024 May 7:17:1771-1780. doi: 10.2147/IDR.S445180. eCollection 2024.

Authors

Cheng Su^#¹, Cai Li^#², Xinyi Hu^#³, Jing Wang^#¹, Linlin Liu^#⁴, Xianfeng Zhang⁴, Yeqing Tong⁴

Affiliations

¹ School of Public Health, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
² Infectious Disease Prevention and Control Center, Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, People's Republic of China.
³ Global Study Institute, University of Geneva, Geneva, 1205, Switzerland.
⁴ Infectious Disease Prevention and Control Center, Hubei Center for Disease Control and Prevention, Wuhan, Hubei, People's Republic of China.

^# Contributed equally.

Abstract

Angiotensin-converting enzyme 2 (ACE2) is an important regulator of the Renin-Angiotensin System (RAS). Additionally, it has been identified as a functional receptor for the Coronavirus. Research indicates that ACE2 plays a role in the regulation of cardiovascular systems by modulating blood pressure and electrolyte balance. Its role in pulmonary diseases has also garnered significant attention due to the widespread prevalence of Coronavirus. There is solid evidence linking ACE2 to other pulmonary diseases, including chronic obstructive pulmonary disease, acute respiratory distress syndrome, allergic asthma, among others. However, the exact pathological and physiological mechanisms of ACE2 in these diseases remain elusive. Our research aims to review and explore the latest advancements in ACE2-related studies in pulmonary diseases. These findings have the potential to open new avenues for utilizing ACE2 as a potential biomarker for early diagnosis and monitoring of pulmonary diseases.

Keywords: ACE2; ARDS; COPD; Lung Cancer; lung diseases.

Publication types

Review

Grants and funding

This study was supported by the National Natural Science Foundation of China (92169117), the Hubei Youth Talent program (2021), the Hubei Public Health Youth Talent program (2021), the Hubei Medical Youth Reserve Talent program (2019), and the Hubei Young Talent Plan (2017) as well as Hubei Outstanding Young Funding Program (2020CFA075).